{"prompt": "['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '53', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', '4.2.1.3', 'Patient-reported Outcomes', 'NOTE: As of Amendment 007-06, ePRO data are no longer being collected.', 'Symptomatic improvement is considered a clinical benefit and accepted by health authorities.', 'As part of the analyses for this study, participants will provide information regarding their', 'health-related quality of life (HRQoL) via the following assessment tools: European', 'Organization for Research and Treatment of Cancer (EORTC) QLQ-C30, EORTC QLQ-', 'LC13, and EuroQoL EQ-5D-5L questionnaires. The ePROs are not pure efficacy or safety', 'endpoints because they are affected by both PD and treatment tolerability.', '4.2.1.3.1', 'EORTC QLQ-C30', 'EORTC QLQ-C30 is the most widely used cancer-specific, HRQoL instrument, which', 'contains 30 items and measures 5 functional dimensions (physical, role, emotional, cognitive,', 'and social), 3 symptom items (fatigue, nausea/vomiting, and pain), 6 single items (dyspnea,', 'sleep disturbance, appetite loss, constipation, diarrhea, and financial impact), and a global', 'health and QoL scale [Aaronson, N. K., et al 1993]. The EORTC QLQ-C30 is a', 'psychometrically and clinically validated instrument appropriate for assessing QoL in', 'oncology studies [Aaronson, N. K., et al 1993].', '4.2.1.3.2', 'EORTC QLQ-LC13', 'The EORTC Quality of Life Questionnaire and Lung Cancer Module 13 (QLQ-LC13), a', 'supplemental lung cancer-specific module used in combination with QLQ-C30, comprises', 'multi-item and single-item measures of lung cancer-associated symptoms (cough,', 'hemoptysis, dyspnea, and site-specific pain) and treatment-related symptoms (sore mouth,', 'dysphagia, peripheral neuropathy, and alopecia) [Bergman, B., et al 1994]. It is scored on a', '4-point scale (1 = not at all, 2 = a little, 3 = quite a bit, 4 = very much) and has been', 'translated and validated into more than 60 languages.', 'The EORTC QLQ-C30 and QLQ-LC13 are the most frequently used PRO measures in lung', 'cancer clinical studies. The reliability, validity, and practicality of these instruments have', 'been reported [Bergman, B., et al 1994) [Aaronson, N. K., et al 1993].', '4.2.1.3.3', 'EuroQoL EQ-5D-5L', 'The EQ-5D-5L is a standardized instrument for use as a measure of health outcome and will', 'provide data to develop health utilities for use in health economic analyses [Rabin, R. 2001].', 'The 5 health state dimensions in the EQ-5D-5L include the following: mobility, self-care,', 'usual activities, pain/discomfort, and anxiety/depression. Each dimension is rated on a 5', 'point scale from 1 (no problem) to 5 (unable to/extreme problems). The EQ-5D-5L also', 'includes a graded (0 to 100) vertical visual analog scale on which the participant rates his or', 'her general state of health at the time of the assessment. This instrument has been used', 'extensively in cancer studies and published results from these studies support its validity and', 'reliability [Pickard, A. S., et al 2007].', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '54', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', '4.2.1.4', 'Pharmacokinetic Enppoints', 'Prior to Amendment 05, blood samples were obtained to measure the PK of pembrolizumab', 'and lenvatinib. The Sponsor has determined sufficient pembrolizumab/lenvatinib PK data in', 'NSCLC participants have been collected. As such, no further PK samples will be collected.', 'Standard PK parameters of clearance (CL) and volume of distribution (V) at steady state are', 'planned to be calculated for lenvatinib when coadministered with pembrolizumab, using the', 'accepted mixed-effects modeling approach. PK data from this study may be combined with', 'data from other studies and analyzed using standard population PK techniques to further', 'characterize basic PK parameters, evaluate the effect of extrinsic and intrinsic factors in', 'support of the proposed dosing regimen, and evaluate safety in the proposed participant', 'population.', '4.2.1.5', 'Planned Exploratory Biomarker Research', 'Cancer immunotherapies represent an important and novel class of antitumor agents.', 'However, the mechanism of action of these exciting new therapies, including novel', 'combinations with antiangiogenesis therapy, is not completely understood and much remains', 'to be learned regarding how best to leverage these new drugs in treating patients. Thus, to aid', 'future patients, it is important to investigate the determinants of response or resistance to', 'cancer immunotherapy and other treatments administered, as well as determinants of AEs in', 'the course of our clinical studies. These efforts may identify novel predictive/PD biomarkers', 'and generate information that may better guide single agent and combination therapy with', 'immuno-oncology drugs. To identify novel biomarkers, biospecimens (ie, blood components,', 'tumor material) will be collected to support analyses of cellular components (eg, protein,', 'deoxyribonucleic acid [DNA], ribonucleic acid [RNA], metabolites) and other circulating', 'molecules. Investigations may include but are not limited to:', 'Germline (blood) genetic analyses (eg, SNP analyses, whole exome sequencing, whole', 'genome sequencing)', 'This research may evaluate whether genetic variation within a clinical study population', 'correlates with response to the treatment(s) under evaluation. If genetic variation is found to', 'predict efficacy or AEs, the data might inform optimal use of therapies in the patient', 'population. Furthermore, it is important to evaluate germline DNA variation across the', 'genome in order to interpret tumor-specific DNA mutations.', 'Genetic (DNA) analyses from tumor', 'The application of new technologies, such as next generation sequencing, has provided', 'scientists the opportunity to identify tumor-specific DNA changes (ie, mutations, methylation', 'status, microsatellite instability) contributing towards the development/progression of cancer', 'and/or driving response to therapy. Key molecular changes of interest to immuno-oncology', 'drug development include the mutational burden of tumors and the clonality of T-cells in the', 'tumor microenvironment. Increased mutational burden (sometimes referred to as a \"hyper-', \"mutated' state) may generate neo-antigen presentation in the tumor microenvironment. To\", 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']\n\n###\n\n", "completion": "END"}